Anidulafungin

제한된
1
C. difficile 위험도
N/A
경구생체이용률
N/A

Dosing

Candidemia, disseminated candidiasisEsophageal candidiasis200 mg IV 1 dose, then 100 mg IV q24h x≥14d after the last positive culture100 mg IV 1 dose, then 50 mg IV q24h x≥14dNo renal dose adjustment

Safety and effectiveness in pediatric patients ≤16y of age have not been established

No dose adjustment

General Information

  • Candidemia

  • Candidiasis of the esophagus

  • Candidiasis of the esophagus - HIV infection

  • Invasive candidiasis, Intra-abdominal and peritonitis

Prior to initiation, obtain specimens for fungal culture and other relevant laboratory studies (including histopathology).

Improvement in signs and symptoms of fungal infection is indicative of efficacy.

Monitor hepatic function during therapy.

Common

  • Hypokalemia

  • Diarrhea

Serious

  • Deep venous thrombosis

  • Abnormal liver function

  • Hepatic necrosis

  • Anaphylaxis

  • Hypersensitivity reaction

  • Seizure

No significant interactions

Antimicrobial class: Antifungal, Echinocandins, Glucans Synthesis Inhibitor

Pregnancy category: B

Average serum half life: 26.5 hours

Urine penetration: Therapeutic

Precautions:

  • Monitoring recommended for liver function test abnormalities.

  • Discontinue use if anaphylactic reactions occur.

  • Risk of metabolic crisis in patients with hereditary fructose intolerance (HFI). Obtain history of HFI symptoms with exposure prior to treatment.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.